[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
스폰서배너광고 안내  배너1 배너2 배너3 배너4
과학으로 본 코로나19 (COVID-19)
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
김도경 (Do Kyung Kim) 저자 이메일 보기
저자CV 보기
63 KB
조회 377  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials
열기 Authors and Affiliations


Evidence from numerous randomised clinical trials suggest that shorter-term antimicrobial therapy is as effective as—and has other advantages over—longer-term antimicrobial regimens at achieving symptomatic cure for acute uncomplicated cystitis. Nevertheless, not all shorter regimens are adopted in clinical guidelines. This study was done to reappraise the treatment duration of each antibiotic in current guidelines for acute uncomplicated cystitis to investigate whether the regimen lengths of guideline approved antibiotics could be reduced.

We systematically searched the PubMed, Embase, and Cochrane Library databases for relevant publications from inception of the databases until Dec 31, 2019. Only randomised clinical trials of women with acute uncomplicated cystitis that assessed antibiotic therapy and reported clinical or microbial response outcome values were included. A network meta-analysis was done and the quality of evidence of all of the included studies was rated. Clinical response was the primary outcome, defined as the complete disappearance of all baseline symptoms at the test-of-cure visit. Bayesian hierarchical random-effects model for dichotomous outcomes was used to compare the efficacy of each antibiotic treatment regimen directly and indirectly. This systematic review is registered in PROSPERO, CRD42018093529.

Overall, 61 randomised clinical trials—which included 20780 patients—were assessed in our systematic review. For the third-generation and fourth-generation fluoroquinolones, a 3-day regimen had similar effect to a single-dose regimen for clinical response (risk ratio [RR] 0·994 [95% credible interval 0·939–1·052] vs 1·024 [0·974–1·083]), with moderate quality of evidence. For pivmecillinam, 5-day and 7-day regimens were similar to a 3-day regimen for clinical response, with moderate quality of evidence (RR 1·041 [0·910–1·193] for the 5-day regimen and 1·095 [0·999–1·203] for the 7-day regimen). Meanwhile, for third-generation cephalosporins and amoxicillin and clavulanate, there was no difference between single-dose and 3-day regimens, but quality of evidence supporting this conclusion was low. For second-generation quinolones and co-trimoxazole, single-dose regimen was less effective than 3-day regimen in clinical response, with moderate quality of evidence.

Treatment duration of the third-generation and fourth-generation quinolones and pivmecillinam could be shorter than the currently recommended regimens for acute uncomplicated cystitis. For other antibiotics, shorter duration of regimens could be considered, but further research is needed because of the low quality of supporting evidence.

- 형식: Research article
- 게재일: 2020년 05월 (BRIC 등록일 2020-05-22)
- 연구진: 국내연구진태극기
- 분야: Medicine, Cancer Biology/Oncology
관련 인터뷰
본 논문은 젊은 여성들에서 흔한 급성방광염에 대한 연구입니다. 현재 여러 가이드라인에서 single dose요법만 있는 fosfomycin trometamol을 제외하고는 다른 항생제 (nitrofurantoin, trimethoprim and sulfamethoxazole, trimethoprim, and pivmecillinam, fluoroquinolones, and β-lactams)에서는 single dose요법을 추천하고 있지않습니다. 하지만 지금...
광유전학의 과거, 현재와 미래[Neuron]
발표: 김윤석 (Stanford University)
일자: 2020년 7월 30일 (목) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
김도경 님 전체논문보기 >
관련분야 논문보기

Cancer Biology/Oncology

Google (by Do Kyung Kim)
Pubmed (by Do Kyung Kim)
e브릭몰(연구용 제품 온라인 구매 사이트)
모집인원: 50명
모집기간: ~7/15
신청조건: BRIC 회원
평가자 혜택

- 참가자 전원 3만원 상품권 제공

제품평가자 모집중
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS